It is expressed on the surface of many TNBCs, making it an attractive target for this malignancy.11, 12 TNBC is a heterogeneous group and tumors with EpCAM overexpression are correlated with poor disease-free and poor overall survival.12 High expression of EpCAM is detected in ~45% of aggressive invasive ductal breast carcinomas cases, whereas invasive lobular breast carcinomas only show high EpCAM expression in 15% of cases.13, 14 While EpCAM was one of the earliest cancer-selective targets identified, drugs targeting it alone have not made significant progress in the clinic. The gene discussed is EPCAM; the disease is invasive ductal breast carcinoma.